Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Randomized, Double-blind, Multiple Dose, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of BI 655066/ABBV-066 (Risankizumab), an IL-23 p19 Antagonist Monoclonal Antibody, in Patients With Moderately to Severely Active Crohn's Disease, Who Are naive to, or Were Previously Treated With Anti-TNF Therapy

Next Previous
X
Search
Trial Profile

A Phase II, Multicenter, Randomized, Double-blind, Multiple Dose, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of BI 655066/ABBV-066 (Risankizumab), an IL-23 p19 Antagonist Monoclonal Antibody, in Patients With Moderately to Severely Active Crohn's Disease, Who Are naive to, or Were Previously Treated With Anti-TNF Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risankizumab (Primary) ; Risankizumab (Primary)
  • Indications Crohn's disease
  • Focus Biomarker; Proof of concept; Therapeutic Use
  • Sponsors AbbVie; Boehringer Ingelheim Pharma KG; Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 20 Aug 2018 Results (n=272) of pooled analysis from phase I and II studies (NCT01577550, NCT02054481 and NCT02031276) published in the Clinical Pharmacokinetics
    • 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week
    • 09 May 2017 Results assesing the efficacy and safety of open-label subcutaneous risankizumab maintenance therapy (n=62) at week 52, presented at the Digestive Disease Week 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top